mTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 27, 2009, Pages 11137-11142

  Shackelford, David B ^a   Vasquez, Debbie S ^a   Corbeil, Jacqueline ^b   Wu, Shulin ^c,d   Leblanc, Mathias ^a   Wu, Chin Lee ^c,d   Vera, David R ^b   Shaw, Reuben J ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AMPK; FDG PET; Glycolysis; Hamartoma; Polyposis

Indexed keywords

FLUORODEOXYGLUCOSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE LKB1; RAPAMYCIN; GLUCOSE; MTORC1 PROTEIN, MOUSE; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; STK11 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; EMBRYO; FIBROBLAST; GASTROINTESTINAL POLYPOSIS; GLUCOSE UTILIZATION; HAMARTOMA; MOUSE; NONHUMAN; PEUTZ JEGHERS SYNDROME; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CELL PROLIFERATION; DISEASE MODEL; DOWN REGULATION; DRUG EFFECT; ENZYMOLOGY; HUMAN; METABOLISM; PATHOLOGY; TUMOR VOLUME;

MAMMALIA; MUS;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FIBROBLASTS; GLUCOSE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; PEUTZ-JEGHERS SYNDROME; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSCRIPTION FACTORS; TUMOR BURDEN; UP-REGULATION;

EID: 67650480092     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0900465106     Document Type: Article

References (59)

1. HemminkiA(1999) The molecular basis and clinical aspects of Peutz-Jeghers syndrome. Cell Mol Life Sci 55:735-750.
2. Sanchez-Cespedes M, et al. (2002) Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 62:3659-3662.
3. Carretero J, Medina PP, Pio R, Montuenga LM, Sanchez-Cespedes M (2004) Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene 23:4037-4040.
4. Ji H, et al. (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448:807-810.
5. Hemminki A, et al. (1998) A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391:184-187.
6. Jenne DE, et al. (1998) Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 18:38-43.
7. Aretz S, et al. (2005) High proportion of large genomic STK11 deletions in Peutz-Jeghers syndrome. Hum Mutat 26:513-519.
8. Hearle NC, et al. (2006) Exonic STK11 deletions are not a rare cause of Peutz-Jeghers syndrome. J Med Genet 43:e15.
9. Ylikorkala A, et al. (2001) Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science 293:1323-1326.
10. Bardeesy N, et al. (2002) Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 419:162-167.
11. Miyoshi H, et al. (2002) Gastrointestinal hamartomatous polyposis in Lkb1 heterozygous knockout mice. Cancer Res 62:2261-2266.
12. Jishage K, et al. (2002) Role of Lkb1, the causative gene of Peutz-Jegher's syndrome, in embryogenesis and polyposis. Proc Natl Acad Sci USA 99:8903-8908.
13. Rossi DJ, et al. (2002) Induction of cyclooxygenase-2 in amouse model of Peutz-Jeghers polyposis. Proc Natl Acad Sci USA 99:12327-12332.
14. Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441:424-430.
15. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9-22.
16. Fingar DC, et al. (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24:200-216.
17. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995-4004.
18. Averous J, Fonseca BD, Proud CG (2008) Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 27:1106-1113.
19. Galmozzi E, et al. (2004) HER2 signaling enhances 5'UTR-mediated translation of c-Myc mRNA. J Cell Physiol 200:82-88.
20. Thomas GV, et al. (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12:122-127.
21. Mills JR, et al. (2008) mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 105:10853-10858.
22. Gwinn DM, et al. (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30:214-226.
23. Inoki K, Zhu T, Guan KL (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577-590.
24. Shaw RJ, et al. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6:91-99.
25. Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL (2004) Regulation of the TSC pathway by LKB1: Evidence of amolecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 18:1533-1538.
26. Shaw RJ, et al. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642-1646.
27. Katajisto P, et al. (2008) LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis. Nat Genet 40:455-459.
28. Raleigh JA, et al. (1998) Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 58:3765-3768.
29. Hsu PP, SabatiniDM(2008) Cancer cell metabolism:Warburg and beyond. Cell 134:703-707.
30. Garber K (2006) Energy deregulation: Licensing tumors to grow. Science 312:1158-1159.
31. Smith TA (2001) The rate-limiting step for tumor [18F]fluoro-2-deoxy-D- glucose (FDG) incorporation. Nucl Med Biol 28:1-4.
32. Stambolic V, et al. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95:29-39.
33. Johannessen CM, et al. (2005) The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA 102:8573-8578.
34. Wei C, et al. (2008) Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling. Clin Cancer Res 14:1167-1171.
35. Wendel HG, et al. (2006) Determinants of sensitivity and resistance to rapamycinchemotherapy drug combinations in vivo. Cancer Res 66:7639-7646.
36. OndaH, et al. (2002) Tsc2 null murine neuroepithelial cells are amodel forhumantuber giant cells, and show activation of an mTOR pathway. Mol Cell Neurosci 21:561-574.
37. RamaswamyS, et al. (1999) Regulation ofG1progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 96:2110-2115.
38. Zhang H, et al. (2003) Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 112:1223-1233.
39. Majumder PK, et al. (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10:594-601.
40. Wendel HG, et al. (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428:332-337.
41. Johannessen CM, et al. (2008) TORC1 is essential for NF1-associated malignancies. Curr Biol 18:56-62.
42. Podsypanina K, et al. (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci USA 98:10320-10325.
43. Lee L, Sudentas P, Dabora SL (2006) Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex. Genes Chromosomes Cancer 45:933-944.
44. Cloughesy TF, et al. (2008) Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8.
45. Hudes G, et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281.
46. Bissler JJ, et al. (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140-151.
47. Davies DM, et al. (2008) Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 358:200-203.
48. Herry I, Neukirch C, Debray MP,Mignon F, Crestani B (2007) Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med 18:76-77.
49. Franz DN, et al. (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59:490-498.
50. Wei LH, et al. (2008) Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res 14:3416-3426.
51. Namba R, et al. (2006) Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin Cancer Res 12:2613-2621.
52. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG, Jr (2003) TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4:147-158.
53. Laderoute KR, et al. (2006) 5-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol 26:5336-5347.
54. Zundel W, et al. (2000) Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14:391-396.
55. Zhong H, et al. (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541-1545.
56. Elstrom RL, et al. (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64:3892-3899.
57. Lum JJ, et al. (2007) The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev 21:1037-1049.
58. Dekanty A, Lavista-Llanos S, Irisarri M, Oldham S, Wappner P (2005) The insulin-PI3K/ TOR pathway induces a HIF-dependent transcriptional response in Drosophila by promoting nuclear localization of HIF-alpha/Sima. J Cell Sci 118:5431-5441.
59. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J (2008) Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type specific repression ofmRNAtranslation. Proc Natl Acad Sci USA 105:17414-17419.